若生智能
Drug Database
HF

HFA Modulite techn

✓ Approved

Chiesi Farmaceutici S.p.A. · 治疗药物

什么是 HFA Modulite techn？

HFA Modulite techn 是一种治疗药物，由Chiesi Farmaceutici S.p.A.研发。该药已获批，用于治疗相关适应症，给药途径：Inhaled。

药物档案

公司Chiesi Farmaceutici S.p.A.
给药途径Inhaled
状态Approved
来源： ClinicalTrials.gov, Chiesi Farmaceutici S.p.A.

治疗适应症

HFA Modulite techn 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedEuropean journal of internal medicine2026-08-02

Particle engineering, aerosol physics, and pulmonary deposition of single-inhaler triple ICS/LABA/LAMA therapies in obstructive airway diseases.

Sorino Claudio C, Virchow Johann Christian JC, Spanevello Antonio A, Buscemi Agata A et al.

Single-inhaler triple therapy (SITT) combining an inhaled corticosteroid, long-acting β2-agonist, and long-acting muscarinic antagonist (ICS/LABA/LAMA) represents the current ceiling of inhaled pharmacotherapy for moderate-to-very-severe chronic obstructive pulmonary disease and severe uncontrolled asthma. Five device platforms are currently approved: two extrafine formulations delivering beclomethasone dipropionate/formoterol/glycopyrronium (the Modulite solution pressurised metered-dose inhaler [pMDI] and the NEXThaler breath-actuated dry powder inhaler [DPI]); the co-suspension pMDI Aerosphere platform (budesonide/glycopyrrolate/formoterol); the standard-particle Ellipta DPI (fluticasone furoate/umeclidinium/vilanterol); and the low-resistance, single-dose capsule-based DPI Breezhaler (mometasone furoate/indacaterol/glycopyrronium). Despite a shared pharmacological class, these systems differ in aerosol physics, particle engineering, intrapulmonary deposition patterns, and device-patient interaction. Furthermore, some of them are authorized only for COPD or asthma. This narrative review examines the technology and in vivo deposition evidence for each SITT platform, discusses real-world performance determinants (particle size, flow dependency, technique robustness), and proposes an expert-informed framework for patient-level device selection. Methodological limitations include reliance on in silico Functional Respiratory Imaging data when in vivo scintigraphy is unavailable, and inconsistent dose denominators across studies (emitted vs. metered dose). Cross-platform comparisons are limited by heterogeneous methodologies, and no SITT platform has demonstrated universal superiority. In platform-specific studies, NEXThaler shows relatively high lung deposition (∼55% of emitted dose) though flow-dependent; Aerosphere is robust to inhalation technique variations; Modulite provides extrafine, peripheral delivery; Ellipta and Breezhaler offer once-daily convenience with moderate deposition. Rational device selection requires structured assessment of patient inspiratory capacity, disease phenotype, coordination, and adherence. Head-to-head scintigraphy and prospective imaging-outcome studies represent major evidence gaps.

PMID 42542404
阅读全文 →
PubMedACS omega2026-08-02

Modulating Luminescence Thermometry of the EuIII/TbIII Pair in Coordination Polymers through Ligand Structure and Lanthanide(III) Molar Ratio.

Araujo Gabriel J S GJS, Souza Talita C TC, de Andrade Stefano A SA, Rodrigues Jéssica F JF et al.

Accurate temperature sensing at the nanoscale has become a powerful tool to monitor heat dissipation in miniaturized systems, driving the development of noncontact luminescent thermometers with high sensitivity. EuIII/TbIII-based coordination polymers are particularly attractive for thermometry due to their structural tunability, which allows the correlation of structural and electronic parameters with thermometric performance. Herein, we compare the luminescence thermometry of a series of one-dimensional coordination polymers, [Ln-(tfa)3(μ-dppeo)]n, [Ln-(tfa)3(μ-dppbo)]n, [Ln-(hfa)3(μ-dppeo)]n, and [Ln-(hfa)3(μ-dppbo)]n (Ln = EuIII, TbIII; tfa-: trifluoroacetylacetonate; hfa-: hexafluoroacetylacetonate; L: [(diphenylphosphoryl)R]-(diphenyl)-phosphine oxide, R = ethyl - dppeo - or butyl - dppbo), focusing on the combined effects of bridge and terminal ligand scaffold as well as lanthanide (LnIII) molar ratio. For each system, the TbIII/EuIII ratio was adjusted to {Tb0.25Eu0.75}n or {Tb0.75Eu0.25}n, enabling systematic evaluation of ratiometric thermometry based on the TbIII 5D4 → 7F5 and EuIII 5D0 → 7F2 emissions. Structural variations induced by the terminal and bridge ligands modulate crystal packing, local coordination microsymmetry, and LnIII-LnIII distances. Coordination polymers with higher TbIII content exhibit enhanced thermometric performance, reaching a maximum relative thermal sensitivity of 5.20% K-1 at 305 K for [Tb0.75Eu0.25(hfa)3(μ-dppbo)]n. The increase of the TbIII amount potentializes the TbIII-to-EuIII energy transfer and enhances the activation energy of the luminescence thermal quenching. These results demonstrate that controlling the ligand scaffold and LnIII molar ratio enables effective modulation of thermal sensitivity and operating range in EuIII/TbIII coordination polymers.

PMID 42540334
阅读全文 →
PubMedIndian journal of ophthalmology2026-07-31

Comparison of virtual reality-based portable perimetry and conventional perimetry in patients with idiopathic intracranial hypertension.

Bozhöyük Gülsüm G GG, Kızıltunç Pınar B PB, Atilla Huban H

To compare a newly developed virtual reality-based perimeter (Oculera visual field analyzer) with the Humphrey Field Analyzer (HFA) in patients with idiopathic intracranial hypertension (IIH). A cross-sectional study. In this study, 30 eyes of 15 IIH patients were randomly tested with HFA (24-2, SITA Standard) and Oculera (24-2, Oculera Interactive) on the same visit. Test durations, global indices [visual field index (VFI), mean deviation (MD), and pattern standard deviation (PSD)], and false negative and positive user responses were compared. Spearman correlation was used for statistical analysis. Correlation analysis showed a statistically significant correlation between the measurements of the two devices in terms of the global indices (VFI, MD, and PSD) and test duration (r = 0.361, P = 0.050; r = 0.395, P = 0.031; r = 0.408, P = 0.025; and r = 0.363, P = 0.049, respectively). The Oculera was within an acceptable range for 83.3% of eyes, considering the MD reproducibility of 1.5-4 dB for HFA. No significant difference was found between the devices in false positive and negative responses ( P = 0.098 and P = 0.395, respectively). Standard automated perimetry is the gold standard for detecting visual field defects, but it is costly and requires prolonged attention and stable fixation. The results of the Oculera, produced with virtual reality technology, were found to be consistent with those of the HFA, and its much lower cost and portability suggest that it has the potential to be an alternative to conventional perimeters.

PMID 42535810
阅读全文 →
PubMedCureus2026-07-30

Patient Blood Management for a Transfusion Dilemma Associated With a Rare Blood Group: A Case Report.

Majeed Zakaa Z, Abu Kahila Farah F, Aijazi Ishma I, Vasudevan Navin Nisha N et al.

Patient blood management (PBM) is a patient-centered, evidence-based approach aimed at improving outcomes by optimizing and preserving a patient's own blood, particularly when transfusion support is limited. We report a 76-year-old female with congestive heart failure and severe mitral stenosis presenting with severe iron deficiency anemia. Transfusion was not feasible due to an alloantibody against a high-frequency antigen (HFA), later identified as anti‑Inᵇ in a rare In(b-) phenotype. The patient was managed conservatively using PBM principles, including intravenous iron therapy, minimization of blood loss, and optimization of physiological tolerance to anemia through infection control. Hemoglobin levels improved steadily, and the patient remained stable without requiring a transfusion. This case highlights the importance of transfusion services and multidisciplinary collaboration in safely managing severe anemia in patients with rare blood groups/antibodies to HFAs.

PMID 42529181
阅读全文 →
PubMedDalton transactions (Cambridge, England : 2003)2026-07-28

Heterobimetallic Ln-Zn (Ln = Eu, Gd) complexes with interesting second order nonlinear optical properties.

Colombo Alessia A, Dragonetti Claudia C, Fagnani Francesco F, Roberto Dominique D et al.

Second-order nonlinear optical chromophores based on coordination compounds offer an interesting route to enhance molecular hyperpolarizability through low-energy charge-transfer excited states and the tunable donor/acceptor character of metal centers. While lanthanide complexes are widely explored for luminescence and magnetism, their second-order NLO properties remain comparatively underinvestigated, and cationic lanthanide systems have, to the best of our knowledge, not been explored. In this context, we designed and synthesized in a simple and rapid way two new lanthanide complexes based on a europium cation or gadolinium cation and the same zinc anion: [Eu(hfa)2(tetrag)]+·[Zn(hfa)3]- and [Gd(hfa)2(tetrag)]+·[Zn(hfa)3]-. Structural and spectroscopic characterization confirms the formation of well-defined cation-anion assemblies in which the lanthanide β-diketonate cation is counterbalanced by a zinc anion counterpart. The second-order nonlinear optical response was evaluated in solution by means of the Electric-Field Induced Second Harmonic generation (EFISH) technique which affords μβEFISH values. Both compounds present values much higher than that of the benchmark Disperse Red One, rendering them of particular interest for future applications such as in electro-optic modulators.

PMID 42517599
阅读全文 →
PubMedJournal of clinical medicine2026-07-28

Heart Failure with Preserved Ejection Fraction in Women with Breast Cancer Prior to Cancer Treatment: Insights from a Cardio-Oncology Assessment.

Battistoni Allegra A, Di Francesco Marco M, Bernardo Davide D, Capparelli Jacopo J et al.

Background: Breast cancer patients are exposed to cardiovascular complications related to both pre-existing cardiovascular risk factors and cardiotoxic cancer therapies. Heart failure with preserved ejection fraction (HFpEF) is an emerging and often under-recognized condition in this population, potentially present before treatment initiation and further influenced by oncologic therapies. This study aimed to characterize baseline HFpEF probability and its longitudinal evolution using validated scoring systems in a real-world cardio-oncology cohort. Methods: We retrospectively evaluated 145 women with breast cancer undergoing baseline cardio-oncology assessment before initiation of potentially cardiotoxic therapies. HFpEF probability was estimated using three validated algorithms (H2FPEF, ABA, and HFA-PEFF). A subgroup of 89 patients underwent exploratory reassessment after 12 ± 3 months to investigate longitudinal changes in HFpEF probability according to treatment. Results: At baseline, HFpEF probability varied substantially according to the scoring system applied, with 14.8-41.5% of patients classified as having intermediate-to-high probability. Agreement among the three algorithms was limited, particularly between HFA-PEFF and H2FPEF/ABA scores. Exploratory longitudinal analyses showed no significant changes in HFpEF probability categories during follow-up. Conclusions: HFpEF probability assessment in breast cancer patients showed substantial baseline heterogeneity across validated scoring systems, with clinically relevant differences in risk classification and limited inter-score agreement. These findings provide novel insights into an underexplored cardio-oncology phenotype and suggest that currently available HFpEF scoring systems may not be directly interchangeable in this clinical setting. Prospective studies including provocative testing are needed to determine the clinical relevance of HFpEF probability scores in breast cancer patients.

PMID 42513653
阅读全文 →

注册免费账户还可查看另外 3397 篇文献

免费注册查看全部文献 →

了解更多HFA Modulite techn